<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children - Pelland-Marcotte, M-C - 2020 | Cochrane Library</title> <meta content="Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children - Pelland-Marcotte, M-C - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005982.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children - Pelland-Marcotte, M-C - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005982.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005982.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children" name="citation_title"/> <meta content="Marie-Claude Pelland-Marcotte" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="Nour Amiri" name="citation_author"/> <meta content="The Hospital for Sick Children" name="citation_author_institution"/> <meta content="Maria L Avila" name="citation_author"/> <meta content="The Hospital for Sick Children" name="citation_author_institution"/> <meta content="Leonardo R Brandão" name="citation_author"/> <meta content="The Hospital for Sick Children" name="citation_author_institution"/> <meta content="leonardo.brandao@sickkids.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD005982.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/06/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005982.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005982.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005982.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [administration &amp; dosage, adverse effects, *therapeutic use]; Catheter Obstruction [statistics &amp; numerical data]; Catheterization, Central Venous [*adverse effects]; Hemorrhage [chemically induced]; Heparin [administration &amp; dosage]; Heparin, Low-Molecular-Weight [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Thrombosis [etiology, *prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005982.pub3&amp;doi=10.1002/14651858.CD005982.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005982\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005982\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005982.pub3",title:"Low molecular weight heparin for prevention of central venous catheter\\u2010related thrombosis in children",firstPublishedDate:"Jun 18, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005982.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005982.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005982.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005982.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005982.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005982.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005982.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005982.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005982.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005982.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5779 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005982.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#CD005982-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#CD005982-sec-0061"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#CD005982-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#CD005982-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#CD005982-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#CD005982-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#CD005982-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#CD005982-sec-0055"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/appendices#CD005982-sec-0066"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/table_n/CD005982StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/table_n/CD005982StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/information#CD005982-cr-0004">Marie-Claude Pelland-Marcotte</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/information#CD005982-cr-0005">Nour Amiri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/information#CD005982-cr-0006">Maria L Avila</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005982.pub3/information#CD005982-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Leonardo R Brandão</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/information/en#CD005982-sec-0074">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 June 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005982.pub3">https://doi.org/10.1002/14651858.CD005982.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005982-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005982-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005982-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005982-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005982-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005982-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005982-abs-0001" lang="en"> <section id="CD005982-sec-0001"> <h3 class="title" id="CD005982-sec-0001">Background</h3> <p>The prevalence of children diagnosed with thrombotic events has been increasing in the last decades. The most common thrombosis risk factor in neonates, infants and children is the placement of a central venous catheter (CVC). It is unknown if anticoagulation prophylaxis with low molecular weight heparin (LMWH) decreases CVC‐related thrombosis in children. This is an update of the Cochrane Review published in 2014. </p> </section> <section id="CD005982-sec-0002"> <h3 class="title" id="CD005982-sec-0002">Objectives</h3> <p>To determine the effect of LMWH prophylaxis on the incidence of CVC‐related thrombosis and major and minor bleeding complications in children. Further objectives were to determine the effect of LMWH on occlusion of CVCs, number of days of CVC patency, episodes of catheter‐related bloodstream infection (CRBSI), other side effects of LMWH (allergic reactions, abnormal coagulation profile, heparin‐induced thrombocytopaenia and osteoporosis) and mortality during therapy. </p> </section> <section id="CD005982-sec-0003"> <h3 class="title" id="CD005982-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL databases and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 7 May 2019. We undertook reference checking of identified trials to identify additional studies. </p> </section> <section id="CD005982-sec-0004"> <h3 class="title" id="CD005982-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐randomised trials comparing LMWH to no prophylaxis (placebo or no treatment), or low‐dose unfractionated heparin (UFH) either as continuous infusion or flushes (low‐dose UFH aims to ensure the patency of the central line but has no systemic anticoagulation activity), given to prevent CVC‐related thrombotic events in children. We selected studies conducted in children aged 0 to 18 years. </p> </section> <section id="CD005982-sec-0005"> <h3 class="title" id="CD005982-sec-0005">Data collection and analysis</h3> <p>Two review authors independently identified eligible studies, which were assessed for study methodology including bias, and extracted unadjusted data where available. In the data analysis step, all outcomes were analysed as binary or dichotomous outcomes. The effects of interventions were summarised with risk ratios (RR) and their respective 95% confidence intervals (CI). We assessed the certainty of evidence for each outcome using the GRADE approach. </p> </section> <section id="CD005982-sec-0006"> <h3 class="title" id="CD005982-sec-0006">Main results</h3> <p>One additional study was included for this update bringing the total to two included studies (with 1135 participants). Both studies were open‐label RCTs comparing LMWH with low‐dose UFH to prevent CVC‐related thrombosis in children. We identified no studies comparing LMWH with placebo or no treatment. Meta‐analysis found insufficient evidence of an effect of LMWH prophylaxis in reducing the incidence of CVC‐related thrombosis in children with CVC, compared to low‐dose UFH (RR 0.68, 95% CI 0.27 to 1.75; 2 studies; 787 participants; low‐certainty evidence). One study (158 participants) reported symptomatic and asymptomatic CVC‐related thrombosis separately and detected no evidence of a difference between LMWH and low‐dose UFH (RR 1.03, 95% CI 0.21 to 4.93; low‐certainty evidence; RR 1.17, 95% CI 0.45 to 3.08; low‐certainty evidence; for symptomatic and asymptomatic participants respectively). There was insufficient evidence to determine whether LMWH impacts the risk of major bleeding (RR 0.27, 95% CI 0.05 to 1.67; 2 studies; 813 participants; low‐certainty evidence); or minor bleeding. One study reported minor bleeding in 53.3% of participants in the LMWH arm and in 44.7% of participants in the low‐dose UFH arm (RR 1.20, 95% CI 0.91 to 1.58; 1 study; 158 participants; very low‐certainty evidence), and the other study reported no minor bleeding in either group (RR: not estimable). Mortality during the study period was reported in one study, where two deaths occurred during the study period. Both were unrelated to thrombotic events and occurred in the low‐dose UFH arm. The second study did not report mortality during therapy per arm but showed similar 5‐year overall survival (low‐certainty evidence). No additional adverse effects were reported. Other pre‐specified outcomes (including CVC occlusion, patency and CRBSI) were not reported. </p> </section> <section id="CD005982-sec-0007"> <h3 class="title" id="CD005982-sec-0007">Authors' conclusions</h3> <p>Pooling data from two RCTs did not provide evidence to support the use of prophylactic LWMH for preventing CVC‐related thrombosis in children (low‐certainty evidence). Evidence was also insufficient to confirm or exclude a difference in the incidence of major and minor bleeding complications in the LMWH prophylaxis group compared to low‐dose UFH (low and very low certainty respectively). No evidence of a clear difference in overall mortality was seen. Studies did not report on the outcomes catheter occlusion, days of catheter patency, episodes of CRBSI and other side effects of LMWH (allergic reactions, abnormal coagulation profile, heparin‐induced thrombocytopaenia and osteoporosis). The certainty of the evidence was downgraded due to risk of bias of the included studies, imprecision and inconsistency, preventing conclusions in regards to the efficacy of LMWH prophylaxis to prevent CVC‐related thrombosis in children. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005982-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005982-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005982-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005982-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005982-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005982-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005982-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD005982-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005982-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005982-abs-0002" lang="en"> <h3>Do blood thinners prevent blood clots in children who are treated using central lines?</h3> <p><b>Background</b> </p> <p>Central lines are thin flexible tubes that are inserted into a person’s vein to provide medical care. They are used to deliver medicines, fluids or nutrients (to feed the patient) directly into the bloodstream. However, they can cause the blood to clot (form into a small lump). This prevents blood from flowing normally in the blood vessels. Blood clots can cause symptoms such as pain or swelling, but can also happen without any symptoms. They can lead to serious health problems and death, if they move and become stuck in major veins or in the lungs. </p> <p>Since the 1990s, blood clots in children in general have become more common, notably due to the rise in blood clots in children treated with central lines. We reviewed the existing research to find out if giving children a blood thinning medicine called low molecular weight heparin (LMWH) protects against blood clots. We also wanted to know whether LMWH increases the risk of minor or severe bleeding, death or other unwanted (adverse) side effects. </p> <p><b>What did we find?</b> </p> <p>We searched the scientific literature in May 2019. We found two studies (one more than when we last searched in 2014). The studies compared what happens in children (aged up to 18 years old) treated using central lines who received LMWH and those who did not. A total of 1135 children were followed for between 30 and 64 days. During that time, the number of blood clots, bleeding episodes and deaths were recorded. One study also looked at the number of deaths five years after treatment. </p> <p>The two studies we found did not allow us to determine with certainty whether or not LMWH protects children with central lines from getting blood clots (with or without symptoms). </p> <p>The studies also did not allow us to determine whether children on LMWH were more likely to experience bleeding (minor or severe), or whether LMWH increases or reduces the risk of death. </p> <p>The two studies did not report any additional adverse effects caused by LMWH.</p> <p><b>Certainty of the evidence</b> </p> <p>We judged the certainty of the evidence to be low for blood clots, low for major bleeding, very low for minor bleeding, and low for mortality. The certainty of the evidence was low or very low because: </p> <p>⦁ there were differences in the way blood clots, bleeding and mortality were measured between studies; </p> <p>⦁ there were few studies and events; and</p> <p>⦁ the researchers and children in the studies knew who was receiving LMWH and who was not, which can influence results. </p> <p>It is likely that future studies will have an important impact on our understanding of the role of LMWH to prevent blood clots and its side effects. </p> <p><b>Conclusion</b> </p> <p>We need more studies on whether LMWH prevents blood clots in children who are treated using central venous lines. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005982-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005982-sec-0061"></div> <h3 class="title" id="CD005982-sec-0062">Implications for practice</h3> <section id="CD005982-sec-0062"> <p>Pooling data from two RCTs provided insufficient evidence of an effect of LMWH prophylaxis in reducing the incidence of CVC‐related thrombosis in children with a CVC, compared to low‐dose UFH (low‐certainty evidence). Evidence was insufficient to determine whether there were differences in the incidence of major and minor bleeding in the LMWH prophylaxis group compared to low‐dose UFH group (low‐ and very low‐certainty respectively). No evidence of a clear difference in overall mortality was seen. Studies did not report on the following outcomes: catheter occlusion, days of catheter patency, episodes of CRBSI, other side effects of LMWH (allergic reactions, abnormal coagulation profile, heparin‐induced thrombocytopaenia and osteoporosis) or adverse effects. The certainty of the evidence was downgraded due to risk of bias of the included studies and inconsistency, preventing conclusions in regards to the efficacy of LMWH prophylaxis to prevent CVC‐related thrombosis in children. Because of the uncertain efficacy of thromboprophylaxis in children, clinicians should practice with caution. </p> </section> <h3 class="title" id="CD005982-sec-0063">Implications for research</h3> <section id="CD005982-sec-0063"> <p>Since the reported incidence of symptomatic CVC‐related thrombosis in children is approximately 10%, a trial evaluating the superiority of LMWH prophylaxis in comparison to standard care or low‐dose UFH will require at least 856 patients in total (that is 428 patients per arm in a one‐to‐one allocation) to achieve 80% power to detect a 50% relative risk reduction of symptomatic thrombosis, which can be considered clinically meaningful. The two‐sided significance level (1‐alpha) was set at 95. We used Open‐Epi software to make this sample size calculation (<a href="./references#CD005982-bbs2-0073" title="OpenEpi: Open Source Epidemiologic Statistics for Public Health. DeanAG , SullivanKM , SoeMM , Version OpenEpi.com, updated 6 April 2013. (accessed 12 June 2020).">OpenEpi</a>). </p> <p>Many lessons can be learned from the included studies. Enrolment was problematic in both studies, either because of the relatively large number of exclusions or because of refusal to receive daily subcutaneous injections with LMWH, especially in young children. This highlights the difficulties of conducting RCTs in paediatric thrombosis. </p> <p>Given the increasing placement of CVCs in modern paediatric care, and that paediatric hospital accreditation may be conditioned to the development of age‐ and scenario‐specific prophylaxis protocol development in the near future, there will be a continued need to conduct trials evaluating this problem. Trials should aim to evaluate the role of patient age, CVC properties, risk factors, and of additional prophylactic modalities such as new oral anticoagulant agents, warfarin and CVC flushes. Lastly, future studies should also address the potential costs of any prophylactic intervention. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005982-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005982-sec-0008"></div> <div class="table" id="CD005982-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Does low molecular weight heparin prevent central venous catheter‐related thrombosis compared to control in children?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low molecular weight heparin (LMWH) for prevention of central venous catheter (CVC)‐related thrombosis in children</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with a CVC<br/><b>Setting:</b> paediatric tertiary care hospital<br/><b>Intervention:</b> LMWH<br/><b>Comparison:</b> control<sup>a</sup> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with LMWH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>CVC‐related thrombosis</b> </p> <p>(follow up ranged from 30 to 64 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.68<br/>(0.27 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>787<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/>(24 to 156) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic CVC‐related thrombosis</b> </p> <p>(assessed with venography;<br/>follow up ranged from 30 to 44 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/>(0.21 to 4.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>158<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/>(8 to 185) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Asymptomatic CVC‐related thrombosis</b> </p> <p>(assessed with venography;<br/>follow up ranged from 30 to 44 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.17<br/>(0.45 to 3.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>158<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000<br/>(39 to 305) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> <p>(assessed with clinical findings;<br/>follow up ranged from 30 days to 64 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.27<br/>(0.05 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>813<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(1 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor bleeding</b> </p> <p>(assessed with clinical findings;<br/>follow up ranged from 30 to 64 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>813<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> reported minor bleeding in 53.3% of patients in the reviparin arm and in 44.7% of patients in the low‐dose UFH arm (RR 1.20, 95% CI 0.91 to 1.58). <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> reported no minor bleeding in either arm. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality during study period</b> </p> <p>(follow up ranged from 30 to 64 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>813<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One study reported two deaths during the study period. Both were unrelated to VTE and occurred in the low‐dose UFH arm (<a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>). One study, including paediatric patients with acute lymphoblastic leukaemia, shows similar 5‐year mortality (<a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CVC</b> : central venous catheter; <b>LMWH</b> : low molecular weight heparin; <b>RR:</b> risk ratio; <b>UFH</b>: unfractionated heparin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Control: In <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> the control group received low‐dose UFH and in <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> the control group received low‐dose UFH flushes<br/><sup>b</sup> Downgraded two steps because of serious risk of bias and inconsistency. Both studies were open‐label trials with no blinding of intervention allocation. In <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>, substantial deviation from the intended intervention might affect results. Both studies reported differing effects of LMWH<br/><sup>c</sup> Downgraded two steps because of serious risk of bias and imprecision. Underpowered study; <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> was closed prematurely due to slow recruitment rate<br/><sup>d</sup> Downgraded two steps because of serious risk of bias and imprecision. Underpowered study; <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> was closed prematurely due to slow recruitment rate<br/><sup>e</sup> Downgraded two steps because of serious risk of bias and imprecision (attributable to small number of events)<br/><sup>f</sup> Downgraded three steps because of serious risk of bias and imprecision (attributable to small number of events) and inconsistency (attributable to important differences in outcome definition)<br/><sup>g</sup> Downgraded two steps because of inconsistency and imprecision (attributable to small number of events) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005982-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005982-sec-0009"></div> <section id="CD005982-sec-0010"> <h3 class="title" id="CD005982-sec-0010">Description of the condition</h3> <p>Central venous catheters (CVC) are widely used for a variety of indications such as monitoring of haemodynamic status and the administration of parenteral nutrition, blood products and chemotherapeutic agents, or the infusion of other fluids (<a href="./references#CD005982-bbs2-0056" title="KlerkCP , SmorenburgSM , BüllerHR . Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Archives of Internal Medicine2003;163(16):1913-21.">Klerk 2003</a>). They are usually divided between non‐tunnelled CVC (centrally‐ and peripherally‐inserted), tunnelled CVC and totally‐implanted CVCs. Although advantageous, and at times life saving, the use of CVCs is associated with mechanical and infectious complications. The major mechanical complications observed are occlusion and thrombosis of the catheter (<a href="./references#CD005982-bbs2-0040" title="Bagnall-ReebHA , RuccioneK . Management of cutaneous reactions and mechanical complications of central venous access devices in pediatric patients with cancer: algorithms for decision making. Oncology Nursing Forum1990;17(5):677-81.">Bagnall‐Reeb 1990</a>; <a href="./references#CD005982-bbs2-0043" title="BonaRD . Central line thrombosis in patients with cancer. Current Opinion in Pulmonary Medicine2003;9(5):362-6.">Bona 2003</a>; <a href="./references#CD005982-bbs2-0051" title="FinkelsteinY , YanivI , BerantM , ZilberR , GartyBZ , EpsteinO , et al. Central venous line thrombosis in children and young adults with thalassemia major. Pediatric Hematology and Oncology2004;21(5):375-81.">Finkelstein 2004</a>; <a href="./references#CD005982-bbs2-0056" title="KlerkCP , SmorenburgSM , BüllerHR . Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Archives of Internal Medicine2003;163(16):1913-21.">Klerk 2003</a>; <a href="./references#CD005982-bbs2-0063" title="MaleC , ChaitP , AndrewM , HannaK , JulianJ , MitchellL , PARKAA Investigators. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood2003;101(11):4237-8.">Male 2003</a>; <a href="./references#CD005982-bbs2-0079" title="SteeleR , IrvinCB . Central line mechanical complication rate in emergency medicine patients. Academic Emergency Medicine2001;8(2):204-7.">Steele 2001</a>; <a href="./references#CD005982-bbs2-0081" title="VidlerV , RichardsM , VoraA . Central venous catheter-associated thrombosis in severe haemophilia. British Journal of Haematology1999;104(3):461-4.">Vidler 1999</a>). The incidence of catheter‐related thrombosis is associated with different factors. Several retrospective and prospective clinical studies have reported incidences of catheter‐related thrombosis ranging between 4% and 66% (<a href="./references#CD005982-bbs2-0038" title="AndrewM , MarzinottoV , PencharzP , ZlotkinS , BurrowsP , IngramJ , et al. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. Journal of Pediatrics1995;126(3):358-63.">Andrew 1995</a>; <a href="./references#CD005982-bbs2-0052" title="FratinoG , MolinariAC , ParodiS , LongoS , SaraccoP , CastagnolaE , et al. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Annals of Oncology2005;16(4):648-54.">Fratino 2005</a>; <a href="./references#CD005982-bbs2-0057" title="Krafte-JacobsB , SivitCJ , MejiaR , PollackMM . Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding. Journal of Pediatrics1995;126(1):50-4.">Krafte‐Jacobs 1995</a>; <a href="./references#CD005982-bbs2-0068" title="MonagleP , ChanAK , GoldenbergNA , IchordRN , JourneycakeJM , Nowak-GöttlU , et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e737S-801S.">Monagle 2012</a>; <a href="./references#CD005982-bbs2-0080" title="VidalE , SharathkumarA , GloverJ , FaustinoEV . Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis2014;12(7):1096-109.">Vidal 2014</a>). More recent studies continue to show the rise of thrombotic events in children, particularly due to the higher incidence of CVC‐related thrombosis (<a href="./references#CD005982-bbs2-0074" title="RaffiniL , HuangYS , WitmerC , FeudtnerC . Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics2009;124(4):1001-8.">Raffini 2009</a>). Several factors have been implicated in causing CVC‐related thrombosis. These include underlying disease, for example, malignancies (<a href="./references#CD005982-bbs2-0010" title="HarlevD , ZaidmanI , SarigG , Ben ArushMW , BrennerB , ElhasidR . Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thrombosis Research2010;126(2):93-7. ">Harlev 2010</a>; <a href="./references#CD005982-bbs2-0065" title="MeisterB , KropshoferG , Klein-FrankeA , StrasakAM , HagerJ , StreifW . Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer2008;50(2):298-303.">Meister 2008</a>; <a href="./references#CD005982-bbs2-0021" title="MitchellL , LambersM , FlegeS , KenetG , Li-Thiao-TeV , HolzhauerS ,  et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood2010;115(24):4999-5004. ">Mitchell 2010</a>); the nature of the substances administered, such as chemotherapeutic agents or hyperosmolar solutions that can cause damage to the vascular endothelium; the site of the catheter, with a higher risk in femoral catheters than those inserted in jugular or subclavian veins (<a href="./references#CD005982-bbs2-0056" title="KlerkCP , SmorenburgSM , BüllerHR . Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Archives of Internal Medicine2003;163(16):1913-21.">Klerk 2003</a>); and the type of catheter (<a href="./references#CD005982-bbs2-0045" title="CardeP , Cosset-DelaigueMF , LaplancheA , ChareauI . Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumors. European Journal of Cancer and Clinical Oncology1989;25(6):939-44.">Carde 1989</a>; <a href="./references#CD005982-bbs2-0064" title="McLeanTW , FisherCJ , SnivelyBM , ChauvenetAR . Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement. Journal of Clinical Oncology2005;23(13):3024-9.">Mclean 2005</a>). The thrombosis related to CVCs can lead to pulmonary embolism (PE), sepsis, stroke or post‐thrombotic syndrome (<a href="./references#CD005982-bbs2-0039" title="AntonN , MassicotteMP . Venous thromboembolism in pediatrics. Seminars in Vascular Medicine2001;1(1):111-22.">Anton 2001</a>), and may require long‐term anticoagulants. </p> </section> <section id="CD005982-sec-0011"> <h3 class="title" id="CD005982-sec-0011">Description of the intervention</h3> <p>In light of the potential morbidity associated with thrombosis‐related complications, thrombosis has become a very clinically relevant complication (<a href="./references#CD005982-bbs2-0025" title="RaffiniL , TrimarchiT , BeliveauJ , DavisD . Thromboprophylaxis in a pediatric hospital: A patient-safety and quality-improvement initiative. Pediatrics2011;127(5):e1326-32. ">Raffini 2011</a>) and anticoagulation prophylaxis has increasingly been considered. Unfractionated heparin (UFH), administered intermittently or as a continuous infusion, has been evaluated for the prevention of thrombotic complications in a few paediatric studies (<a href="./references#CD005982-bbs2-0075" title="RandolphAG , CookDJ , GonzalesCA , AndrewM . Benefit of heparin in central venous and pulmonary artery catheters:a meta-analysis of randomized controlled trials. Chest1998;113(1):165-71.">Randolph 1998</a>; <a href="./references#CD005982-bbs2-0078" title="ShahPS , ShahVS . Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD002772.pub3]">Shah 2008</a>). However, the benefits of using UFH have to be weighted against the risks of allergic reactions, heparin‐induced thrombocytopaenia and bleeding complications secondary to errors in the dosage. On the other hand, low molecular weight heparin (LMWH) has the advantages of having a longer half‐life, increased bioavailability, ease of administration and capability for careful monitoring in children (<a href="./references#CD005982-bbs2-0039" title="AntonN , MassicotteMP . Venous thromboembolism in pediatrics. Seminars in Vascular Medicine2001;1(1):111-22.">Anton 2001</a>; <a href="./references#CD005982-bbs2-0068" title="MonagleP , ChanAK , GoldenbergNA , IchordRN , JourneycakeJM , Nowak-GöttlU , et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e737S-801S.">Monagle 2012</a>). In the absence of convincing prospective paediatric studies, recent guidelines do not support primary prophylaxis for children with CVCs (<a href="./references#CD005982-bbs2-0046" title="ChalmersE , GanesenV , LiesnerR , MarooS , NokesT , SaundersD , et al, British Committee for Standards in Haematology. Guidelines on the investigation, management and prevention of venous thrombosis in children. British Journal of Haematology2011;154(2):196-207.">Chalmers 2011</a>; <a href="./references#CD005982-bbs2-0068" title="MonagleP , ChanAK , GoldenbergNA , IchordRN , JourneycakeJM , Nowak-GöttlU , et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e737S-801S.">Monagle 2012</a>). </p> </section> <section id="CD005982-sec-0012"> <h3 class="title" id="CD005982-sec-0012">How the intervention might work</h3> <p>LMWH, an anticoagulant drug from the family of heparinoids that is available in several formulations, has been successfully used as a prophylactic regimen for CVCs in adults with cancer (<a href="./references#CD005982-bbs2-0055" title="KahaleLA , HakoumMB , TsolakianIG , AlturkiF , MatarCF , TerrenatoI , et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database of Systematic Reviews2018, Issue 6. [DOI: 10.1002/14651858.CD006650.pub5]">Kahale 2018</a>). For example, at a dose of 2500 IU daily given subcutaneously, the LMWH dalteparin proved to be effective and safe in preventing the development of CVC‐related deep venous thrombosis (DVT) in adult cancer patients. The incidence of venography‐proven thrombosis was 6% in the prophylaxis group versus 62% in the placebo group (relative risk (RR) of thrombosis with prophylaxis: 0.15, 95% confidence interval (CI) 0.02 to 0.95; P = 0.002) and no bleeding complications developed (<a href="./references#CD005982-bbs2-0022" title="MonrealM , AlastrueA , RullM , MiraX , MuxartJ , RosellR , et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thrombosis and Haemostasis1996;75(2):251-3. ">Monreal 1996</a>). </p> </section> <section id="CD005982-sec-0013"> <h3 class="title" id="CD005982-sec-0013">Why it is important to do this review</h3> <p>The aim of this review was to evaluate the efficacy and safety of LMWH for the prevention of CVC‐related thrombosis in children. A previous systematic review did not show a beneficial effect of LMWH to reduce CVC‐related thrombosis (<a href="./references#CD005982-bbs2-0080" title="VidalE , SharathkumarA , GloverJ , FaustinoEV . Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis2014;12(7):1096-109.">Vidal 2014</a>). We aimed to reflect the addition of recently conducted studies to aid decision making for healthcare professionals and patients. This is an update of the Cochrane Review published in 2014 (<a href="./references#CD005982-bbs2-0082" title="BrandaoLR , ShahN , ShahPS . Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD005982.pub2]">Brandao 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005982-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005982-sec-0014"></div> <p>To determine the effect of LMWH prophylaxis on the incidence of CVC‐related thrombosis and major and minor bleeding complications in children. Further objectives were to determine the effect of LMWH on occlusion of CVCs, number of days of CVC patency, episodes of catheter‐related bloodstream infection (CRBSI), other side effects of LMWH (allergic reactions, abnormal coagulation profile, heparin‐induced thrombocytopaenia, and osteoporosis) and mortality during therapy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005982-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005982-sec-0015"></div> <section id="CD005982-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005982-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) of LMWH in children with CVCs. Studies that used alternative methods of randomisation such as alternate days of the week, odd or even date of birth, or hospital number (quasi‐randomised trials) were eligible for inclusion. We did not include studies that used historical controls. For any studies in which the unit of randomisation was the catheter, we planned to contact the primary authors to obtain data for the first catheter after randomisation, but this was not required. </p> </section> <section id="CD005982-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included children (age one month to 18 years) who required CVCs during their course of treatment either while in hospital or after discharge. The definition of CVC encompassed single‐ and multi‐lumen non‐tunnelled catheters (centrally‐ and peripherally‐inserted central catheters), tunnelled catheters and totally‐implanted catheters, with or without heparin‐bonding or antimicrobial impregnation. </p> </section> <section id="CD005982-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing LMWH versus low‐dose UFH. The use of low‐dose UFH continuous infusion or flushes (intermittent injection of a small amount of UFH) is a common clinical practice to ensure the patency of the central line, despite the lack of evidence of its beneficial effect for the prevention of CVC occlusion in both children and adults (<a href="./references#CD005982-bbs2-0044" title="BradfordNK , EdwardsRM , ChanRJ . Normal saline (0.9% sodium chloride) versus heparin intermittent flushing for the prevention of occlusion in long-term central venous catheters in infants and children. Cochrane Database of Systematic Reviews2020, Issue 4. [DOI: 10.1002/14651858.CD010996.pub3]">Bradford 2020</a>; <a href="./references#CD005982-bbs2-0062" title="López‐BrizE , GarciaVR , CabelloJB , Bort‐MartíS , SanchisRC , BurlsA . Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD008462.pub3]">López‐Briz 2018</a>). We also planned to include trials comparing LMWH versus no prophylactic heparin (placebo or no treatment), but this practice was not used in either of the included trials. LMWH, placebo or UFH must have been administered during the entire time the catheter was in place. </p> </section> <section id="CD005982-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We included trials that reported on one or more of the following outcomes amongst the randomised participants. </p> <section id="CD005982-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD005982-list-0001"> <li> <p>CVC‐related thrombosis (along the length of, or at the tip of, the catheter) as determined by either colour duplex Doppler ultrasonography or contrast venography, with or without clinical suspicion (symptomatic or asymptomatic). This was determined as dichotomous data (yes or no). We intended to obtain the incidence of CVC‐related thrombosis (number of thrombosis by 1000 catheter‐days), if data were available. A CVC‐related thrombosis was considered symptomatic if clinical signs or symptoms of thrombosis were present, including but not restricted to oedema, pain or erythema (<a href="./references#CD005982-bbs2-0059" title="LeeAY , LevineMN , ButlerG , WebbC , CostantiniL , GuC , et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. Journal of Clinical Oncology2006;24(9):1404-8.">Lee 2006</a>). </p> </li> <li> <p>Major and minor bleeding complications, defined as follows (<a href="./references#CD005982-bbs2-0067" title="MitchellLG , GoldenbergNA , MaleC , KenetG , MonagleP , Nowak‐GöttlU , Perinatal and Paediatric Haemostasis Subcommittee of the SSC of the ISTH . Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. Journal of Thrombosis and Haemostasis2011;9(9):1856-8.">Mitchell 2011</a>): </p> <ul id="CD005982-list-0002"> <li> <p>Major bleeding: fatal bleeding, clinically overt bleeding associated with a decrease in haemoglobin of at least 20 g/L in a 24 hours period, bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the central nervous system; and bleeding that requires surgical intervention in an operating suite </p> </li> <li> <p>Minor bleeding: any overt or macroscopic evidence of bleeding that does not fulfil the above criteria for major bleeding </p> </li> </ul> </li> </ul> </p> </section> <section id="CD005982-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD005982-list-0003"> <li> <p>Occlusion of the catheter. This was determined as dichotomous data (yes or no). The catheter occlusion could be partial (blood cannot be aspirated through the catheter but infusion is possible) or complete (neither aspiration nor infusion possible) (<a href="./references#CD005982-bbs2-0042" title="BaskinJL , PuiCH , ReissU , WilimasJA , MetzgerML , RibeiroRC , et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet2009;374(9684):159-69.">Baskin 2009</a>). We also intended to obtain the incidence of catheter occlusion using the number of occlusions/1000 catheter‐days if data were available. </p> </li> <li> <p>Days of catheter patency (duration of patency of first catheter, in days).</p> </li> <li> <p>Episodes of catheter‐related bloodstream infection (CRBSI), defined as a bloodstream infection in a patient with an intravascular catheter with at least one positive blood culture and with clinical manifestations of infections (i.e., fever, chills, and/or hypotension) and no apparent source of infection, in addition to adequate microbiological evidence of catheter‐related infection (<a href="./references#CD005982-bbs2-0066" title="MermelLA , AllonM , BouzaE , CravenDE , FlynnP , O'GradyNP , et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases2009;49(1):1-45.">Mermel 2009</a>). </p> </li> <li> <p>Other side effects of LMWH (allergic reactions, abnormal coagulation profile, heparin‐induced thrombocytopaenia, osteoporosis). For the purpose of this review, heparin‐induced thrombocytopaenia was defined as an intermediate or high clinical probability of heparin‐induced thrombocytopaenia using the 4Ts score coupled with a positive immunoassay or functional assay (<a href="./references#CD005982-bbs2-0048" title="CukerA , ArepallyGM , ChongBH , CinesDB , GreinacherA , GruelY , et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances2018;2(22):3360-92.">Cuker 2018</a>). </p> </li> <li> <p>Mortality during the period of therapy.</p> </li> <li> <p>Any other reported adverse outcomes (not pre‐specified).</p> </li> </ul> </p> </section> </section> </section> <section id="CD005982-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005982-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases for randomised controlled trials and controlled clinical trials without language, publication year or publication status restrictions: </p> <p> <ul id="CD005982-list-0004"> <li> <p>the Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web searched on 7 May 2019); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) Cochrane Register of Studies Online (CRSO 2019, 4); </p> </li> <li> <p>MEDLINE (Ovid MEDLINE® Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE®) (searched from 1 January 2017 to 7 May 2019); </p> </li> <li> <p>Embase Ovid (searched from 1 January 2017 to 7 May 2019);</p> </li> <li> <p>CINAHL Ebsco (searched from 1 January 2017 to 7 May 2019);</p> </li> <li> <p>AMED Ovid (searched from 1 January 2017 to 7 May 2019).</p> </li> </ul> </p> <p>The Information Specialist modelled search strategies for other databases on the search strategy designed for CENTRAL. Where appropriate, they were combined with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying RCTs and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 6, <a href="./references#CD005982-bbs2-0060" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org.">Lefebvre 2011</a>). Search strategies for major databases are provided in <a href="./appendices#CD005982-sec-0067">Appendix 1</a>. </p> <p>The Information Specialist searched the following trials registries on 7 May 2019:</p> <p> <ul id="CD005982-list-0005"> <li> <p>the World Health Organization International Clinical Trials Registry Platform (<a href="http://who.int/trialsearch" target="_blank">who.int/trialsearch</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). </p> </li> </ul> </p> </section> <section id="CD005982-sec-0025"> <h4 class="title">Searching other resources</h4> <p>In addition, we searched the reference lists of identified trials.</p> </section> </section> <section id="CD005982-sec-0026"> <h3 class="title" id="CD005982-sec-0026">Data collection and analysis</h3> <section id="CD005982-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MPM, NA) independently assessed all published articles identified as potentially relevant by the literature search for inclusion in the review. Discrepancies were resolved by consensus, with consultation of a third review author (LRB or MLA) if necessary. In order to be included, the trial had to meet the following criteria: </p> <p> <ul id="CD005982-list-0006"> <li> <p>the study population were children (age one month to 18 years);</p> </li> <li> <p>the intervention was LMWH compared with placebo, no treatment or low‐dose UFH (flushes or continuous infusion) for CVCs; </p> </li> <li> <p>the study was a randomised or quasi‐randomised controlled trial;</p> </li> <li> <p>one or more primary or secondary outcome measures were reported.</p> </li> </ul> </p> </section> <section id="CD005982-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MPM, NA) independently extracted data from the retrieved articles. We contacted the primary authors of any articles for which there was inadequate information, or where relevant data could not be abstracted. Discrepancies were resolved by consensus, with consultation of a third review author (LRB or MLA) if necessary. </p> </section> <section id="CD005982-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of the included studies using Cochrane's 'Risk of bias' tool (<a href="./references#CD005982-bbs2-0054" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. available from handbook.cochrane.org (accessed 10 July 2019).">Higgins 2017</a>). The risk of bias was classified as low, high or unclear for each of the following domains: bias in selection of participants onto the study, performance bias, detection bias, bias due to missing data, and bias in selection of the reported results. Two review authors independently performed this evaluation (MPM, NA), and discussed disagreements to reach a consensus. </p> </section> <section id="CD005982-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated RRs and 95% CIs as a measure of treatment effect. For continuous scales of measurements, we planned to analyse using mean difference (MD) with a 95% CI, where the same scales were used. </p> </section> <section id="CD005982-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The individual participant was the unit of analysis. There were no studies that included a cross‐over or cluster‐randomised design. If there are such studies in future updates, we will include and analyse them as appropriate. We planned to perform analysis separately for studies using CVC as the unit of analysis, but no included study used this approach. </p> </section> <section id="CD005982-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the corresponding authors via e‐mail up to three times in order to obtain missing data. In the meta‐analysis, we used a complete‐case analysis approach, where participants considered to have missing data were excluded from the analysis. This type of analysis assumes that data is missing at random. In the event of concerns that data appeared to be not missing at random and that a difference was found between groups, we planned to perform sensitivity analysis as described below. </p> </section> <section id="CD005982-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested heterogeneity and variability between trials using the Chi‐square test for heterogeneity (with the significance threshold set at P &lt; 0.10), as well as the I<sup>2</sup> statistic. I<sup>2</sup> values above 50% indicate the possibility of substantial heterogeneity. We evaluated meta‐analyses exceeding this threshold and inspected their individual studies to identify possible sources of heterogeneity. </p> </section> <section id="CD005982-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to investigate publication bias using funnel plots if 10 or more studies were identified. </p> </section> <section id="CD005982-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Data were presented descriptively. We utilised Review Manager software to perform data analysis (<a href="./references#CD005982-bbs2-0076" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). When we were able to pool data we used a random‐effects method based on the inverse variance approach under the assumption that the effects being estimated in the different studies are not identical due to the clinical and methodological heterogeneity of the included studies. </p> </section> <section id="CD005982-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analyses according to the control intervention:</p> <p> <ul id="CD005982-list-0007"> <li> <p>LMWH versus placebo or no treatment;</p> </li> <li> <p>LMWH versus low‐dose UFH (flushes or continuous infusion).</p> </li> </ul> </p> <p>Given the limited number of studies retrieved, we did not carry out subgroup analyses. If sufficient numbers of studies are available in the future, we will perform these. </p> </section> <section id="CD005982-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform a sensitivity analysis to assess the impact of risk of bias on the effects of the intervention by excluding studies with one or more domains at high risk of bias from the analysis. </p> <p>To test the robustness of findings to bias arising from missing data, in the event of concerns that data appeared to be not missing at random, we also planned to perform sensitivity analysis, with and without inclusion of studies with a substantial drop‐out rate. We defined 'substantial' as a drop‐out rate equal to or greater than the event rate of the control group, </p> <p>Given the limited number of studies retrieved, we did not carry out sensitivity analyses. If in future updates sufficient studies are included, we will carry out sensitivity analyses. </p> </section> <section id="CD005982-sec-0038"> <h4 class="title">Summarising findings and assessment of certainty of the evidence</h4> <p>We included a 'Summary of findings' table in this review to present the most important findings, including the certainty of evidence for the outcomes considered to be most clinically relevant. These outcomes were chosen in accordance with a suggested core set of outcomes for trials on the prevention of thromboembolic events (<a href="./references#CD005982-bbs2-0067" title="MitchellLG , GoldenbergNA , MaleC , KenetG , MonagleP , Nowak‐GöttlU , Perinatal and Paediatric Haemostasis Subcommittee of the SSC of the ISTH . Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. Journal of Thrombosis and Haemostasis2011;9(9):1856-8.">Mitchell 2011</a>), identified in the Core Outcome Measures in Effectiveness Trials (COMET) database. Certainty of the evidence was determined using the GRADE approach, which considers the overall risk of bias of the included studies, the directness of the evidence, inconsistency within the results, precision of the effect estimate and the risk of publication bias (<a href="./references#CD005982-bbs2-0041" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):61-6.">Balshem 2011</a>; <a href="./references#CD005982-bbs2-0053" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck-YtterY , SchunemannHJ , et al. What is "Quality of evidence" and why is it important to clinicians?BMJ2008;336(7651):995-8.'>Guyatt 2008</a>). The outcomes included in the 'Summary of findings' table were CVC‐related thrombosis; CVC‐related symptomatic thrombosis; CVC‐related asymptomatic thrombosis; major bleeding; minor bleeding and mortality. We created the 'Summary of findings' table using <a href="https://archie.cochrane.org/sections/documents/view?document=265400030712001076&amp;format=REVMAN#REF-GRADEpro-GDT-2015" target="_blank">GRADEpro GDT 2015</a> software. See <a href="./full#CD005982-tbl-0001">summary of findings Table 1</a>. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005982-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005982-sec-0039"></div> <section id="CD005982-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD005982-sec-0041"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD005982-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD005982-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD005982-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>In this update, we included and assessed one new study (<a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>). We excluded 15 studies (<a href="./references#CD005982-bbs2-0004" title="BehzadB , MohammadAA , LadanS , ArmindokhtS , AliS . Evaluating the effect of high dose versus low dose heparin in peripherally inserted central catheter in very low birth weight infants. Iranian Journal of Pediatrics2018;28(3):1-6. ">Barekatain 2018</a>; <a href="./references#CD005982-bbs2-0006" title="CefaliM , FregoniV , PiacentiniG , SansiC , GervasoL , PavesiL , et al. Is there a role for antithrombotic prophylaxis in oncologic patients who undergo central venous access placement?European Journal of Cancer2017;72 (Supplement 1):S140. ">Cefali 2017</a>; <a href="./references#CD005982-bbs2-0008" title="Del PrincipeMI , MaurilloL , SarloC , BuccisanoF , CefaloM , VendittiD , et al. Factors that increase the risk of central venous catheter-related thrombosis in acute myeloid leukemia: a prospective, randomized experience. Thrombosis Research2012;10:s136. ">Del Principe 2012</a>; <a href="./references#CD005982-bbs2-0009" title="DiamondCE , HennesseyC , MeldauJ , GuelcherCJ , GuerreraMF , ConklinLS , et al. Catheter-related venous thrombosis in hospitalized pediatric patients with inflammatory bowel disease: incidence, characteristics, and role of anticoagulant thromboprophylaxis with enoxaparin. Journal of Pediatrics2018;198:53-9. ">Diamond 2018</a>; <a href="./references#CD005982-bbs2-0013" title="KorkemazM , BellR , ValleeM , ElftouhN , CartierP , RenaldA , et al. Tin-cat study: Conversion of unfractionned heparin to tinzaparin in hemodialysis and its impact on alteplase (cathflo) utilization. Nephrology Dialysis Transplantation2017;32 (Supplement 3):iii286. ">Korkemaz 2017</a>; <a href="./references#CD005982-bbs2-0014" title="KurtkotiJ , BoseB , HiremagalurB , SunJ , CochraneT . Arterial line versus venous line administration of low molecular weight heparin, enoxaparin for prevention of thrombosis in the extracorporeal blood circuit of patients on haemodialysis or haemodiafiltration: a randomized cross-over trial. Nephrology2016;21(8):663-8. ">Kurtkoti 2016</a>; <a href="./references#CD005982-bbs2-0015" title="LamontagneF , ZytarukN , DhingraV , LeeA , ChittockD , MeadeM , et al. Risk of thromboses from peripherally inserted central catheters (PICCs) in the ICU. American Journal of Respiratory and Critical Care Medicine2014;189:A4464. ">Lamontagne 2014</a>; <a href="./references#CD005982-bbs2-0016" title="Lavau-DenesS , LacroixP , MaubonA , Preux PM , GenetD , Venat-BouvetL , et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemotherapy and Pharmacology2013;72(1):65-73. ">Lavau‐Denes 2013</a>; <a href="./references#CD005982-bbs2-0017" title="LiRF , CuiXQ , XuLP . Anticoagulant effect of low molecular weight heparin on central venous catheters in haemodialysis patients. Tropical Journal of Pharmaceutical Research2016;15(12):2733-8. ">Li 2016</a>; <a href="./references#CD005982-bbs2-0018" title="LutkinM , StronachL , YadavP , HothiDK . Dalteparin anticoagulation in paediatric home haemodialysis. Pediatric Nephrology2018;33(12):2337-41. ">Lutkin 2018</a>; <a href="./references#CD005982-bbs2-0019" title="McDonaldMM , JohnsonML , RumackCM , MarlarR , HathawayWE . Heparin prevention of catheter related thromboses. Pediatric Research1984;18:335A. ">McDonald 1984</a>; <a href="./references#CD005982-bbs2-0024" title="PardunN , LemmerJ , BelkerK , PringsheimM , HagerA , EwertP , et al. Low molecular weight heparin administered by subcutaneous catheter is a safe and effective anticoagulation regimen in selected inpatient infants and children with complex congenital heart disease. In: Cardiology in the Young. Vol. 27 (4). 2017:S460. ">Pardun 2017</a>; <a href="./references#CD005982-bbs2-0026" title="NCT00311896. Efficacy and safety of prophylaxis with bemiparin in cancer patients with a central venous catheter (BECAT). clinicaltrials.gov/ct2/show/NCT00311896 (first received 6 April 2006). ">Rocha 2006</a>; <a href="./references#CD005982-bbs2-0028" title="ThirunavukkarasuM , SivalingamM . Dalteparin is a safe and effective alternative to unfractionated heparin for extra-corporeal anti coagulation. Indian Journal of Nephrology2016;26 (8 Supplement 1):S71. ">Thirunavukkarasu 2016</a>; <a href="./references#CD005982-bbs2-0033" title="WangX , WangS , Morse MA , JiangN , ZhaoY , SongY , et al. Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. Journal of Thrombosis and Thrombolysis2019;47(4):505-11. ">Wang 2019</a>). We identified two ongoing studies (<a href="./references#CD005982-bbs2-0034" title="KlaassenIL , LauwMN , Van De WeteringMD , BiemondBJ , MiddeldorpS , Abbink FC et al. TropicALL study: Thromboprophylaxis in children treated for Acute Lymphoblastic Leukemia with low-molecular-weight heparin: a multicenter randomized controlled trial. BMC Pediatrics2017;17(1):122-9. ">Klassen 2017</a>; <a href="./references#CD005982-bbs2-0035" title="NCT03003390. Prevention of central venous catheter-associated thrombosis in critically ill children: a multicenter phase 2b trial. clinicaltrials.gov/ct2/show/NCT03003390 (first received 28 December 2016). ">NCT03003390</a>). </p> </section> <section id="CD005982-sec-0042"> <h4 class="title">Included studies</h4> <p>We identified one new study for this update (<a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>). Our review thus includes two studies with a total of 1135 participants enrolled (<a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>; <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>). Both studies compared LMWH (reviparin or enoxaparin) with low‐dose unfractionated heparin (UFH). We identified no studies comparing LMWH with placebo or no treatment. See <a href="./references#CD005982-sec-0080" title="">Characteristics of included studies</a>. </p> <p><a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> included 186 children randomised to receive either LMWH (reviparin) prophylaxis (mean age 6.1 yr, standard deviation (SD) 5.2 yr) or standard care, that is, low‐dose UFH &lt; 3 IU/kg body weight/hour (mean age 6.4 yr, SD 5.0 yr) for prevention of CVC‐related thrombosis (symptomatic or asymptomatic, or both) or thrombosis‐related death. Additionally, the most common and relevant complication related to LMWH use, bleeding, was analysed between study arms. The study's inclusion criteria for participants were neonates, infants and children admitted to the hospital with a newly placed CVC that were subsequently screened by examination or by imaging at CVC removal. During CVC placement, patients randomised to the intervention arm received an age‐appropriate LMWH dose to prevent thrombosis development. Patients randomised to the standard care arm received low‐dose heparin flushes or infusions (not equivalent to systemic anticoagulation). The outcomes reported were the rate of CVC‐related thrombosis, symptomatic and asymptomatic confirmed CVC‐related thrombosis, death due to VTE, major and minor bleeding events in both arms within 30 days of CVC placement or at the time of CVC removal (+ 14 days if &lt; 30 days). Separate data for neonates and non‐neonates were not presented separately and are therefore presented together in this review. </p> <p><a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> recruited 949 children with newly‐diagnosed acute lymphoblastic leukaemia receiving induction chemotherapy as per the treatment protocols ALL‐BFM 2000 (<a href="./references#CD005982-bbs2-0069" title="NCT00430118. Combination chemotherapy based on risk of relapse in treating young patients with acute lymphoblastic leukemia. clinicaltrials.gov/ct2/show/NCT00430118 (first received 1 February 2007).">NCT00430118</a>) or AIEOP‐BFM‐ALL 2009 (<a href="./references#CD005982-bbs2-0070" title="NCT01117441. International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. clinicaltrials.gov/ct2/show/NCT01117441 (first received 5 May 2010).">NCT01117441</a>) in a three‐arm open‐label RCT in Germany and Switzerland. Participants were randomised to either activity‐adapted antithrombin preparation, which will not be discussed further in this review, prophylactic LMWH (enoxaparin) at 80 to 100 IU/kg from day 8 to day 33 of induction (age: 1 to &lt; 6 yrs: 49.5%; 6 to &lt; 10 yrs: 22.9%; ≥ 10 yrs: 27.8%), or low‐dose UFH at a dose of 2 IU/kg body weight/hour (1 to &lt; 6 yrs: 55.8%;, 6 &lt; 10 yrs: 18.3%; ≥ 10 yrs: 26.0%), for prevention of CVC‐related thrombosis. The outcomes included: thrombosis (objectively proven by imaging following clinical suspicion), bleeding events, overall survival and event‐free survival, as measured over an observation period of 64 days. </p> </section> <section id="CD005982-sec-0043"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD005982-sec-0081" title="">Characteristics of excluded studies</a>. </p> <p>We excluded 15 studies in this update (<a href="./references#CD005982-bbs2-0004" title="BehzadB , MohammadAA , LadanS , ArmindokhtS , AliS . Evaluating the effect of high dose versus low dose heparin in peripherally inserted central catheter in very low birth weight infants. Iranian Journal of Pediatrics2018;28(3):1-6. ">Barekatain 2018</a>; <a href="./references#CD005982-bbs2-0006" title="CefaliM , FregoniV , PiacentiniG , SansiC , GervasoL , PavesiL , et al. Is there a role for antithrombotic prophylaxis in oncologic patients who undergo central venous access placement?European Journal of Cancer2017;72 (Supplement 1):S140. ">Cefali 2017</a>; <a href="./references#CD005982-bbs2-0008" title="Del PrincipeMI , MaurilloL , SarloC , BuccisanoF , CefaloM , VendittiD , et al. Factors that increase the risk of central venous catheter-related thrombosis in acute myeloid leukemia: a prospective, randomized experience. Thrombosis Research2012;10:s136. ">Del Principe 2012</a>; <a href="./references#CD005982-bbs2-0009" title="DiamondCE , HennesseyC , MeldauJ , GuelcherCJ , GuerreraMF , ConklinLS , et al. Catheter-related venous thrombosis in hospitalized pediatric patients with inflammatory bowel disease: incidence, characteristics, and role of anticoagulant thromboprophylaxis with enoxaparin. Journal of Pediatrics2018;198:53-9. ">Diamond 2018</a>; <a href="./references#CD005982-bbs2-0013" title="KorkemazM , BellR , ValleeM , ElftouhN , CartierP , RenaldA , et al. Tin-cat study: Conversion of unfractionned heparin to tinzaparin in hemodialysis and its impact on alteplase (cathflo) utilization. Nephrology Dialysis Transplantation2017;32 (Supplement 3):iii286. ">Korkemaz 2017</a>; <a href="./references#CD005982-bbs2-0014" title="KurtkotiJ , BoseB , HiremagalurB , SunJ , CochraneT . Arterial line versus venous line administration of low molecular weight heparin, enoxaparin for prevention of thrombosis in the extracorporeal blood circuit of patients on haemodialysis or haemodiafiltration: a randomized cross-over trial. Nephrology2016;21(8):663-8. ">Kurtkoti 2016</a>; <a href="./references#CD005982-bbs2-0015" title="LamontagneF , ZytarukN , DhingraV , LeeA , ChittockD , MeadeM , et al. Risk of thromboses from peripherally inserted central catheters (PICCs) in the ICU. American Journal of Respiratory and Critical Care Medicine2014;189:A4464. ">Lamontagne 2014</a>; <a href="./references#CD005982-bbs2-0016" title="Lavau-DenesS , LacroixP , MaubonA , Preux PM , GenetD , Venat-BouvetL , et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemotherapy and Pharmacology2013;72(1):65-73. ">Lavau‐Denes 2013</a>; <a href="./references#CD005982-bbs2-0017" title="LiRF , CuiXQ , XuLP . Anticoagulant effect of low molecular weight heparin on central venous catheters in haemodialysis patients. Tropical Journal of Pharmaceutical Research2016;15(12):2733-8. ">Li 2016</a>; <a href="./references#CD005982-bbs2-0018" title="LutkinM , StronachL , YadavP , HothiDK . Dalteparin anticoagulation in paediatric home haemodialysis. Pediatric Nephrology2018;33(12):2337-41. ">Lutkin 2018</a>; <a href="./references#CD005982-bbs2-0019" title="McDonaldMM , JohnsonML , RumackCM , MarlarR , HathawayWE . Heparin prevention of catheter related thromboses. Pediatric Research1984;18:335A. ">McDonald 1984</a>; <a href="./references#CD005982-bbs2-0024" title="PardunN , LemmerJ , BelkerK , PringsheimM , HagerA , EwertP , et al. Low molecular weight heparin administered by subcutaneous catheter is a safe and effective anticoagulation regimen in selected inpatient infants and children with complex congenital heart disease. In: Cardiology in the Young. Vol. 27 (4). 2017:S460. ">Pardun 2017</a>; <a href="./references#CD005982-bbs2-0026" title="NCT00311896. Efficacy and safety of prophylaxis with bemiparin in cancer patients with a central venous catheter (BECAT). clinicaltrials.gov/ct2/show/NCT00311896 (first received 6 April 2006). ">Rocha 2006</a>; <a href="./references#CD005982-bbs2-0028" title="ThirunavukkarasuM , SivalingamM . Dalteparin is a safe and effective alternative to unfractionated heparin for extra-corporeal anti coagulation. Indian Journal of Nephrology2016;26 (8 Supplement 1):S71. ">Thirunavukkarasu 2016</a>; <a href="./references#CD005982-bbs2-0033" title="WangX , WangS , Morse MA , JiangN , ZhaoY , SongY , et al. Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. Journal of Thrombosis and Thrombolysis2019;47(4):505-11. ">Wang 2019</a>); bringing the total number of excluded studies to 31. Exclusion reasons were: trials run exclusively in the adult care setting (<a href="./references#CD005982-bbs2-0003" title="AbdelkefiA , Ben OthmanT , KammounL , ChelliM , RomdhaneNB , KriaaA , et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. Thrombosis and Haemostasis2004;92(3):654-61. ">Abdelkefi 2004</a>; <a href="./references#CD005982-bbs2-0007" title="De CiccoM , MatovicM , BalestreriL , SteffanA , PacenziaR , MalafronteM , et al. Early and short-term acenocumarine or dalteparin for the prevention of central venous catheter-related thrombosis in cancer patients: a randomized controlled study based on venographies. Annals of Oncology2009;20(12):1936-42. ">De Cicco 2009</a>; <a href="./references#CD005982-bbs2-0008" title="Del PrincipeMI , MaurilloL , SarloC , BuccisanoF , CefaloM , VendittiD , et al. Factors that increase the risk of central venous catheter-related thrombosis in acute myeloid leukemia: a prospective, randomized experience. Thrombosis Research2012;10:s136. ">Del Principe 2012</a>; <a href="./references#CD005982-bbs2-0012" title="KarthausM , KretzschmarA , KroningH , BiakhovM , IrwinD , MarschnerN , et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Annals of Oncology2006;17(2):289-96. ">Karthaus 2006</a>; <a href="./references#CD005982-bbs2-0014" title="KurtkotiJ , BoseB , HiremagalurB , SunJ , CochraneT . Arterial line versus venous line administration of low molecular weight heparin, enoxaparin for prevention of thrombosis in the extracorporeal blood circuit of patients on haemodialysis or haemodiafiltration: a randomized cross-over trial. Nephrology2016;21(8):663-8. ">Kurtkoti 2016</a>; <a href="./references#CD005982-bbs2-0015" title="LamontagneF , ZytarukN , DhingraV , LeeA , ChittockD , MeadeM , et al. Risk of thromboses from peripherally inserted central catheters (PICCs) in the ICU. American Journal of Respiratory and Critical Care Medicine2014;189:A4464. ">Lamontagne 2014</a>; <a href="./references#CD005982-bbs2-0016" title="Lavau-DenesS , LacroixP , MaubonA , Preux PM , GenetD , Venat-BouvetL , et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemotherapy and Pharmacology2013;72(1):65-73. ">Lavau‐Denes 2013</a>; <a href="./references#CD005982-bbs2-0017" title="LiRF , CuiXQ , XuLP . Anticoagulant effect of low molecular weight heparin on central venous catheters in haemodialysis patients. Tropical Journal of Pharmaceutical Research2016;15(12):2733-8. ">Li 2016</a>; <a href="./references#CD005982-bbs2-0020" title="MismettiP , MilleD , LaporteS , CharletV , Buchmüller-CordierA , JacquinJP , et al, CIP Study Group. Low molecular weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica2003;88(1):67-73. ">Mismetti 2003</a>; <a href="./references#CD005982-bbs2-0022" title="MonrealM , AlastrueA , RullM , MiraX , MuxartJ , RosellR , et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thrombosis and Haemostasis1996;75(2):251-3. ">Monreal 1996</a>; <a href="./references#CD005982-bbs2-0023" title="NiersTM , Di NisioM , KlerkCP , BaarslagHJ , BullerHR , BiemondBJ . Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. Journal of Thrombosis and Haemostasis2007;5(9):1878-82. ">Niers 2007</a>; <a href="./references#CD005982-bbs2-0026" title="NCT00311896. Efficacy and safety of prophylaxis with bemiparin in cancer patients with a central venous catheter (BECAT). clinicaltrials.gov/ct2/show/NCT00311896 (first received 6 April 2006). ">Rocha 2006</a>; <a href="./references#CD005982-bbs2-0028" title="ThirunavukkarasuM , SivalingamM . Dalteparin is a safe and effective alternative to unfractionated heparin for extra-corporeal anti coagulation. Indian Journal of Nephrology2016;26 (8 Supplement 1):S71. ">Thirunavukkarasu 2016</a>; <a href="./references#CD005982-bbs2-0032" title="VersoM , AgnelliG , BertoglioS , Di SommaFC , PaolettiF , AgenoW , et al. Enoxaparin for prevention of thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. Journal of Clinical Oncology2005;23(18):4057-62. ">Verso 2005</a>; <a href="./references#CD005982-bbs2-0033" title="WangX , WangS , Morse MA , JiangN , ZhaoY , SongY , et al. Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. Journal of Thrombosis and Thrombolysis2019;47(4):505-11. ">Wang 2019</a>) or in neonates aged less than 30 days old (<a href="./references#CD005982-bbs2-0004" title="BehzadB , MohammadAA , LadanS , ArmindokhtS , AliS . Evaluating the effect of high dose versus low dose heparin in peripherally inserted central catheter in very low birth weight infants. Iranian Journal of Pediatrics2018;28(3):1-6. ">Barekatain 2018</a>; <a href="./references#CD005982-bbs2-0019" title="McDonaldMM , JohnsonML , RumackCM , MarlarR , HathawayWE . Heparin prevention of catheter related thromboses. Pediatric Research1984;18:335A. ">McDonald 1984</a>); prospective cohort studies (<a href="./references#CD005982-bbs2-0013" title="KorkemazM , BellR , ValleeM , ElftouhN , CartierP , RenaldA , et al. Tin-cat study: Conversion of unfractionned heparin to tinzaparin in hemodialysis and its impact on alteplase (cathflo) utilization. Nephrology Dialysis Transplantation2017;32 (Supplement 3):iii286. ">Korkemaz 2017</a>; <a href="./references#CD005982-bbs2-0021" title="MitchellL , LambersM , FlegeS , KenetG , Li-Thiao-TeV , HolzhauerS ,  et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood2010;115(24):4999-5004. ">Mitchell 2010</a>; <a href="./references#CD005982-bbs2-0025" title="RaffiniL , TrimarchiT , BeliveauJ , DavisD . Thromboprophylaxis in a pediatric hospital: A patient-safety and quality-improvement initiative. Pediatrics2011;127(5):e1326-32. ">Raffini 2011</a>; <a href="./references#CD005982-bbs2-0029" title="TrameMN , MitchellL , KrümpelA , MaleC , HempelG , Nowak-GöttlU . Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. Journal of Thrombosis and Haemostasis2010;8(9):1950-8. ">Trame 2010</a>); retrospective cohort studies (<a href="./references#CD005982-bbs2-0005" title="CavoM , WangW , O'BrienSH . Use of low molecular weight heparin for thromboprophylaxis in a pediatric inpatient population: reasons for use and incidence of bleeding complications. Thrombosis Research2010;125(4):370-2. ">Cavo 2010</a>; <a href="./references#CD005982-bbs2-0006" title="CefaliM , FregoniV , PiacentiniG , SansiC , GervasoL , PavesiL , et al. Is there a role for antithrombotic prophylaxis in oncologic patients who undergo central venous access placement?European Journal of Cancer2017;72 (Supplement 1):S140. ">Cefali 2017</a>; <a href="./references#CD005982-bbs2-0009" title="DiamondCE , HennesseyC , MeldauJ , GuelcherCJ , GuerreraMF , ConklinLS , et al. Catheter-related venous thrombosis in hospitalized pediatric patients with inflammatory bowel disease: incidence, characteristics, and role of anticoagulant thromboprophylaxis with enoxaparin. Journal of Pediatrics2018;198:53-9. ">Diamond 2018</a>; <a href="./references#CD005982-bbs2-0010" title="HarlevD , ZaidmanI , SarigG , Ben ArushMW , BrennerB , ElhasidR . Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thrombosis Research2010;126(2):93-7. ">Harlev 2010</a>; <a href="./references#CD005982-bbs2-0011" title='HarneyKM , McCabeM , BranowickiP , KalishLA , NeufeldEJ . Observational cohort study of pediatric inpatients with central venous catheters at "intermediate risk" of thrombosis and eligible for anticoagulant prophylaxis. Journal of Pediatric Oncology Nursing2010;27(6):325-9. '>Harney 2010</a>; <a href="./references#CD005982-bbs2-0018" title="LutkinM , StronachL , YadavP , HothiDK . Dalteparin anticoagulation in paediatric home haemodialysis. Pediatric Nephrology2018;33(12):2337-41. ">Lutkin 2018</a>; <a href="./references#CD005982-bbs2-0024" title="PardunN , LemmerJ , BelkerK , PringsheimM , HagerA , EwertP , et al. Low molecular weight heparin administered by subcutaneous catheter is a safe and effective anticoagulation regimen in selected inpatient infants and children with complex congenital heart disease. In: Cardiology in the Young. Vol. 27 (4). 2017:S460. ">Pardun 2017</a>; <a href="./references#CD005982-bbs2-0027" title="SandovalJA , SheehanMP , StonerockCE , ShafiqueS , RescorlaFJ , DalsingMC . Incidence, risk factors and treatment patterns for deep venous thrombosis in hospitalized children: an increasing population at risk. Journal of Vascular Surgery2008;47(4):837-43. ">Sandoval 2008</a>; <a href="./references#CD005982-bbs2-0030" title="vanOmmenCH , TabbersMM . Catheter-related thrombosis in children with intestinal failure and long-term parenteral nutrition: how to treat and to prevent?Thrombosis Research2010;126(6):465-70. ">van Ommen 2010</a>) and mixed design (<a href="./references#CD005982-bbs2-0031" title="VegtingIL , TabbersMM , BenningaMA , WIldeJC , SerlieMJ , TasTA , et al. Prophylactic anticoagulation decreases catheter-related thrombosis and occlusion in children with home parenteral nutrition. Journal of Parenteral and Enteral Nutrition2012;36(4):456-62. ">Vegting 2012</a>). </p> </section> </section> <section id="CD005982-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias of the included studies (<a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>, <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>) is shown in <a href="#CD005982-fig-0002">Figure 2</a> and is explained in detail in <a href="./references#CD005982-sec-0080" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD005982-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005982-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD005982-sec-0045"> <h4 class="title">Allocation</h4> <p>In both studies, participants were randomised using a computer‐derived protocol and so are at low risk of bias in this domain. Allocation concealment was judged to be at low risk of bias in <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> and at unclear risk of bias in <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> as it was not specifically addressed and the study author has not provided this information. </p> </section> <section id="CD005982-sec-0046"> <h4 class="title">Blinding</h4> <p>No blinding of participants and study personnel occurred in either study, leading to a high risk of performance bias in both studies (<a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>; <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>). <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> had an unclear risk for detection bias. Physicians and radiologists were aware of the randomisation arm but appropriate methods were used to diagnose the outcomes (i.e. appropriate radiological studies for thrombosis and transparent clinical criteria for bleeding, based on standardized definitions (<a href="./references#CD005982-bbs2-0077" title="SchulmanS , KearonC , Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>; <a href="./references#CD005982-bbs2-0061" title="LevineMN , RaskobG , LandefeldS , KearonC . Hemorrhagic complications of anticoagulant treatment. Chest2001;119:108S-21S.">Levine 2001</a>; <a href="./references#CD005982-bbs2-0047" title="Committee for proprietary medicinal products (CPMP). Notes for guidance on clinical investigation of medicinal products for treatment of venous thromboembolic disease (2016). www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-clinical-investigation-medicinal-products-treatment-venous-thromboembolic-disease_en.pdf (accessed 19 September 2019).">Committee for proprietary medicinal products 2016</a>)). These methods might have reduced (without removing entirely) the risk of bias. The study by Massicotte was felt to be at low risk of detection bias because of the placement of an independent and blinded outcome adjudication process (<a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>). </p> </section> <section id="CD005982-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>The risk of attrition bias was considered high in one study (<a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>). For 28 participants (15%) no data were available regarding the efficacy outcome (venogram proven VTE), because the required venogram could not be performed (23 participants, 12 in the intervention arm and 11 in the control arm) or was inconclusive (two in the intervention arm and three in the control arm). In the second study, the rates of attrition were low (seven patients, two in the enoxaparin arm and five in the UFH arm) and was caused by deaths of participants (<a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>). </p> </section> <section id="CD005982-sec-0048"> <h4 class="title">Selective reporting</h4> <p>Both studies were felt to be at low risk of reporting bias. The study protocol of <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> was not available, but the published report included all expected outcomes. The study protocol of <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> was provided as an online supplement and the report included all expected outcomes. </p> </section> <section id="CD005982-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>In <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>, the study was stopped early due to the low enrolment rate (not due to data‐driven reasons) and was underpowered. However, this was not thought to introduce any potential bias. </p> <p>Two additional sources of bias were identified in <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>. First, refusal of antithrombotic treatment, especially by children less than 6 years of age, led to substantial deviations from the intended interventions (10/312 (3%) in participants randomised to UFH, 105/317 (33%) in participants assigned to enoxaparin). These deviations might lead to under‐estimation of the efficacy of the enoxaparin and under‐estimation of the risk of bleeding. Additionally, the study protocol of <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> was amended to allow participation of patients without a CVC, which has an unclear effect on the results. The study authors have not provided additional information about the allocation of included patients without a CVC, leading to a judgement of high risk of other potential bias. </p> </section> </section> <section id="CD005982-sec-0050"> <h3 class="title" id="CD005982-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD005982-tbl-0001"><b>Summary of findings 1</b> Does low molecular weight heparin prevent central venous catheter‐related thrombosis compared to control in children?</a> </p> <section id="CD005982-sec-0051"> <h4 class="title">All CVC‐related thrombosis</h4> <p>Individually, the studies reported conflicting results. <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> found no clear evidence of a difference in the incidence of CVC‐related thrombosis between patients in the LMWH (reviparin) arm and the low‐dose UFH arm (RR 1.13, 95% CI 0.51 to 2.50). However, the study was not powered to detect the efficacy of LMWH prophylaxis to prevent CVC‐related thrombosis in children, given the early closure of the study. Conversely, in <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>, the risk of thromboembolism was moderately reduced by LMWH (enoxaparin) compared to the low‐dose UFH arm (RR 0.43, 95% CI 0.22 to 0.88). </p> <p>Pooling the data in a meta‐analysis showed insufficient evidence of an effect of LMWH prophylaxis in reducing the incidence of CVC‐related thrombosis compared to low‐dose UFH (RR 0.68, 95% CI 0.27 to 1.75; 2 trials; 787 participants; low‐certainty evidence; <a href="./references#CD005982-fig-0003" title="">Analysis 1.1</a>). Of note, I<sup>2</sup> was 68%, suggesting substantial heterogeneity. The certainty of evidence was downgraded two steps because of serious risk of bias and inconsistency. </p> <p>One study reported symptomatic and asymptomatic CVC‐related thrombosis separately and showed no evidence of a difference in both instances (<a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>) (symptomatic thrombosis: RR 1.03, 95% CI 0.21 to 4.93; 1 trial; 158 participants; low‐certainty evidence; <a href="./references#CD005982-fig-0004" title="">Analysis 1.2</a>; asymptomatic: RR 1.17, 95% CI 0.45 to 3.08; 1 trial; 158 participants; low‐certainty evidence; <a href="./references#CD005982-fig-0005" title="">Analysis 1.3</a>). For both symptomatic and asymptomatic CVC‐related thrombosis, the certainty of evidence was downgraded two steps because of serious risk of bias and imprecision. </p> <p>No further information was available regarding the remaining pre‐specified secondary outcomes, including catheter occlusion, days of catheter patency, episodes of CRBSI, and other side effects of LMWH (allergic reactions, abnormal coagulation profile, heparin‐induced thrombocytopaenia and osteoporosis). </p> </section> <section id="CD005982-sec-0052"> <h4 class="title">Major bleeding</h4> <p>Both studies reported on major bleeding, with six major bleeding events encountered among 813 participants (0.7%) (one in the LMWH group, five in the low‐dose UFH group). There is insufficient evidence to determine whether LMWH impacts the risk of bleeding due to imprecision and risk of bias in the included studies (RR 0.27, 95% CI 0.05 to 1.67; 2 trials; 813 participants, low‐certainty evidence; <a href="./references#CD005982-fig-0006" title="">Analysis 1.4</a>). No heterogeneity was detected for this analysis (I<sup>2</sup> = 0%). </p> </section> <section id="CD005982-sec-0053"> <h4 class="title">Minor bleeding</h4> <p>In <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>, minor bleeding was found in 53.3% of participants in the reviparin arm and in 44.7% of participants in the low‐dose UFH arm (RR 1.20, 95% CI 0.91 to 1.58; 1 trial; 158 participants; very low‐certainty evidence; <a href="./references#CD005982-fig-0007" title="">Analysis 1.5</a>). No minor bleeding in either arms was reported in <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> (RR: not estimable). The results were not pooled because of important differences in baseline rates of minor bleeding, likely attributable to differences in outcome definition. <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> defined minor bleeding as any bleeding event exceeding what was usually expected, where <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> used more stringent criteria to define minor bleeding that were clinically relevant but did not met the criteria of a major bleeding. </p> </section> <section id="CD005982-sec-0054"> <h4 class="title">Mortality</h4> <p>Both studies reported mortality but did not find evidence of clear differences between study arms. <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> reported two deaths during the study period. Both were unrelated to VTE and occurred in the low‐dose UFH arm. <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>, which included paediatric patients with acute lymphoblastic leukaemia, showed similar 5‐year all‐cause mortality (5‐year overall survival: enoxaparin: 90.9 ± 1.6%, low‐dose UFH: 92.4 ± 1.5%). The number of deaths during the intervention was not available per arm. </p> <p>We were unable to pool the data for this outcome because of the differences in outcome reporting. We judged the certainty of the evidence for this outcome to be low due to inconsistency and imprecision (attributable to small number of events). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005982-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005982-sec-0055"></div> <section id="CD005982-sec-0056"> <h3 class="title" id="CD005982-sec-0056">Summary of main results</h3> <p>This review update found insufficient evidence of an effect of LMWH prophylaxis in reducing the incidence of CVC‐related thrombosis in children with a CVC, compared to low‐dose UFH (low‐certainty evidence). Only one study reported asymptomatic and symptomatic thrombosis, again showing no evidence of a difference between LWMH prophylaxis compared to heparin flushes (low‐certainty evidence). Similarly, there is insufficient evidence of any effect regarding the risk of major bleeding (low‐certainty evidence); minor bleeding (very low‐certainty evidence); or overall mortality following thromboprophylaxis with LMWH. Reported deaths were not thrombosis‐related. We were limited by the number of trials meeting the inclusion criteria. The two studies which were included did not report on other pre‐specified outcomes including CVC occlusion, days of CVC patency, CRBSI or other adverse effects of LMWH. See <a href="./full#CD005982-tbl-0001">summary of findings Table 1</a>. </p> </section> <section id="CD005982-sec-0057"> <h3 class="title" id="CD005982-sec-0057">Overall completeness and applicability of evidence</h3> <p>The included studies compared LMWH with low‐dose UFH. We identified no studies comparing LMWH with placebo or no treatment. This reflects the current practice, as the use of low‐dose UFH continuous infusion or flushes is commonly used to ensure the patency of the CVC. </p> <p>Children requiring a CVC are a highly complex and heterogenous population. They have different underlying conditions and may be exposed to different types of CVCs, with variable risk of CVC‐related complications and thrombosis. The included studies recruited participants with a limited number of conditions, thus leading to an under‐representation of several patient populations and CVCs. <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> included children with a variety of health conditions requiring CVC placement but was underpowered due to the early closure of the trial, while <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> recruited exclusively children with acute lymphoblastic leukaemia receiving induction chemotherapy. Thus, the findings might not be applicable to all paediatric patients admitted to tertiary care hospitals with a CVC, such as children admitted to the paediatric intensive care unit. A recent cross‐sectional international survey has shown that among children admitted to the paediatric intensive care unit, 52.8% had at least one CVC. Only 17.0% received some form of pharmacological thromboprophylaxis (<a href="./references#CD005982-bbs2-0049" title="FaustinoEV , HansonS , SpinellaPC , TucciM , O'BrienSH , NunezAR , et al. PROphylaxis against ThRombosis prACTice (PROTRACT) Study Investigators of the PALISI BloodNet. A multinational study of thromboprophylaxis practice in critically ill children. Critical Care Medicine2014;42(5):1232-40.">Faustino 2014</a>). Unfortunately, we found no data to evaluate several secondary outcomes of this review, including the impact of the intervention on catheter patency. </p> </section> <section id="CD005982-sec-0058"> <h3 class="title" id="CD005982-sec-0058">Quality of the evidence</h3> <p>The included trials had an adequate methodological design (<a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>; <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>) and thorough report, including the study limitations and deviations from the protocol. Some limitations should however be highlighted. One study had an important deviation from the intended intervention based on refusal of subcutaneous injections in the LMWH arm (<a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>). Additionally, both were open‐label studies, due to the ethical and practical challenges of using a placebo for subcutaneous injections, which in theory may increase the estimate of intervention effects. Nonetheless, in <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>, a committee for outcome adjudication was in place, decreasing the risk of bias in this respect. No system was in place to blind the attending physician or radiologist to the treatment arm in <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>, and radiological assessment was solely based on clinical suspicion, thereby leading to some bias in outcome detection. However, investigators used appropriate standardized definitions of the outcomes. </p> <p>We found substantial heterogeneity in our main analysis. The small number of studies did not allow further analysis to explore potential causes of heterogeneity. Possible explanations for heterogeneity include differences in underlying conditions of the study populations (varied versus acute lymphoblastic leukaemia), differences in LMWH used (reviparin versus enoxaparin) and differences in outcome assessment (systematic venogram at study exit versus radiologic evaluation based on clinical assessment). The International Society on Thrombosis and Haemostasis (ISTH) recommends the inclusion of any radiologically confirmed DVT, whether clinically apparent or asymptomatic, because acutely asymptomatic VTE not uncommonly presents with functional sequelae; and because of the insensitivity and non‐specificity of the clinical diagnosis of DVT in children (<a href="./references#CD005982-bbs2-0050" title="FaustinoEVS . Central venous catheter-associated deep venous thrombosis in critically ill children. Seminars in Thrombosis and Hemostasis2018;44(1):52-6.">Faustino 2018</a>, <a href="./references#CD005982-bbs2-0067" title="MitchellLG , GoldenbergNA , MaleC , KenetG , MonagleP , Nowak‐GöttlU , Perinatal and Paediatric Haemostasis Subcommittee of the SSC of the ISTH . Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. Journal of Thrombosis and Haemostasis2011;9(9):1856-8.">Mitchell 2011</a>). </p> <p>As a result, the risk of bias and the imprecision of the results prompted us to downgrade the certainty of the evidence from high to low for CVC‐related thrombosis and from high to low or very low for major and minor bleeding, respectively (<a href="./full#CD005982-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD005982-sec-0059"> <h3 class="title" id="CD005982-sec-0059">Potential biases in the review process</h3> <p>We searched for published and unpublished abstracts and manuscripts in a comprehensive literature review designed and run by the Cochrane Vascular Information Specialist. This search was not limited to a particular language. We contacted study authors to obtain data that were missing in the original publications or abstracts. However, a limitation of this review is the fact that it was not possible to collect all relevant information from the included trials: 1) outcomes not included in the study such as efficacy data regarding CVC patency and safety data regarding osteoporosis, coagulopathy, heparin‐induced thrombocytopaenia and allergic reactions secondary to LMWH use, 2) data on relevant subset of patients not available, e.g. separate data for patients who did not have a CVC in place in <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> and separate data for neonates and non‐neonates in <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>. </p> </section> <section id="CD005982-sec-0060"> <h3 class="title" id="CD005982-sec-0060">Agreements and disagreements with other studies or reviews</h3> <p>This review found insufficient evidence of a difference in the incidence of CVC‐related thrombosis despite LMWH prophylaxis. Four other studies suggested differently and warrant a closer look (<a href="./references#CD005982-bbs2-0009" title="DiamondCE , HennesseyC , MeldauJ , GuelcherCJ , GuerreraMF , ConklinLS , et al. Catheter-related venous thrombosis in hospitalized pediatric patients with inflammatory bowel disease: incidence, characteristics, and role of anticoagulant thromboprophylaxis with enoxaparin. Journal of Pediatrics2018;198:53-9. ">Diamond 2018</a>; <a href="./references#CD005982-bbs2-0010" title="HarlevD , ZaidmanI , SarigG , Ben ArushMW , BrennerB , ElhasidR . Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thrombosis Research2010;126(2):93-7. ">Harlev 2010</a>; <a href="./references#CD005982-bbs2-0021" title="MitchellL , LambersM , FlegeS , KenetG , Li-Thiao-TeV , HolzhauerS ,  et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood2010;115(24):4999-5004. ">Mitchell 2010</a>; <a href="./references#CD005982-bbs2-0031" title="VegtingIL , TabbersMM , BenningaMA , WIldeJC , SerlieMJ , TasTA , et al. Prophylactic anticoagulation decreases catheter-related thrombosis and occlusion in children with home parenteral nutrition. Journal of Parenteral and Enteral Nutrition2012;36(4):456-62. ">Vegting 2012</a>). They were reports from single institution studies (<a href="./references#CD005982-bbs2-0010" title="HarlevD , ZaidmanI , SarigG , Ben ArushMW , BrennerB , ElhasidR . Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thrombosis Research2010;126(2):93-7. ">Harlev 2010;</a><a href="./references#CD005982-bbs2-0031" title="VegtingIL , TabbersMM , BenningaMA , WIldeJC , SerlieMJ , TasTA , et al. Prophylactic anticoagulation decreases catheter-related thrombosis and occlusion in children with home parenteral nutrition. Journal of Parenteral and Enteral Nutrition2012;36(4):456-62. ">Vegting 2012</a>; <a href="./references#CD005982-bbs2-0009" title="DiamondCE , HennesseyC , MeldauJ , GuelcherCJ , GuerreraMF , ConklinLS , et al. Catheter-related venous thrombosis in hospitalized pediatric patients with inflammatory bowel disease: incidence, characteristics, and role of anticoagulant thromboprophylaxis with enoxaparin. Journal of Pediatrics2018;198:53-9. ">Diamond 2018</a>), and from one multicentre collaborative study (<a href="./references#CD005982-bbs2-0021" title="MitchellL , LambersM , FlegeS , KenetG , Li-Thiao-TeV , HolzhauerS ,  et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood2010;115(24):4999-5004. ">Mitchell 2010</a>). These studies were not randomised, increasing study limitations and the potential for bias. </p> <p>Populations carrying different risks due to their different nature could vary in their thrombosis risks, providing a reasonable explanation for the differences seen between the studies. The studies by <a href="./references#CD005982-bbs2-0010" title="HarlevD , ZaidmanI , SarigG , Ben ArushMW , BrennerB , ElhasidR . Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thrombosis Research2010;126(2):93-7. ">Harlev 2010</a> and <a href="./references#CD005982-bbs2-0021" title="MitchellL , LambersM , FlegeS , KenetG , Li-Thiao-TeV , HolzhauerS ,  et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood2010;115(24):4999-5004. ">Mitchell 2010</a> analysed the incidence of thrombosis in children with the most common form of paediatric cancer, acute lymphoblastic leukaemia (ALL). <a href="./references#CD005982-bbs2-0010" title="HarlevD , ZaidmanI , SarigG , Ben ArushMW , BrennerB , ElhasidR . Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thrombosis Research2010;126(2):93-7. ">Harlev 2010</a> was a study including children treated over a nine‐year period (1999 to 2008). Their overall thrombosis incidence was 7.5%, and patients carrying an inherited thrombotic risk factor (factor V Leiden or prothrombin gene mutation) received upfront LMWH prophylaxis (enoxaparin 1 mg/kg body weight/dose, once daily) during the most thrombogenic phases of their chemotherapy protocol. The group with thrombophilia and LMWH had a thrombosis incidence of 16.6%, much lower than the previous historical report in the same subpopulation but without LMWH (~ 47%) (<a href="./references#CD005982-bbs2-0071" title="Nowak-GöttlU , WermesC , JunkerR , KochHG , SchobessR , FleischhackG , et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood1999;93(5):1595-9.">Nowak‐Göttl 1999</a>). The incidence in the low‐risk patients was 4.5% (<a href="./references#CD005982-bbs2-0010" title="HarlevD , ZaidmanI , SarigG , Ben ArushMW , BrennerB , ElhasidR . Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thrombosis Research2010;126(2):93-7. ">Harlev 2010</a>). Half of those thrombotic events occurred in patients with CVCs. <a href="./references#CD005982-bbs2-0021" title="MitchellL , LambersM , FlegeS , KenetG , Li-Thiao-TeV , HolzhauerS ,  et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood2010;115(24):4999-5004. ">Mitchell 2010</a> also looked at children with ALL. Thrombosis risk stratification was done using a newly developed thrombosis risk stratification score. Four hundred fifty‐six participants were available for scoring and 339 for prospective validation of the score. Subsequently, 8/19 children scoring at high thrombotic risk received LMWH primary prophylaxis prior to CVC placement; LMWH was instituted based on physicians' preferences. This practice led to a significant increased thrombosis‐free survival in patients on LMWH (P = 0.02, log rank test). Therefore, both studies suggested a beneficial preventive antithrombotic effect in children with ALL and CVC placement. These results align with the included study in this review by <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>, which also reported a reduction of thrombosis in children with ALL. Conversely, the proportions of the two main underlying conditions in <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> were congenital heart disease (22.5%) and cancer (50%). It is possible that ALL is a more homogenous and potentially more thrombogenic condition, in which thromboprophylaxis might be more effective. In fact, even within the same underlying condition, as shown in <a href="./references#CD005982-bbs2-0021" title="MitchellL , LambersM , FlegeS , KenetG , Li-Thiao-TeV , HolzhauerS ,  et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood2010;115(24):4999-5004. ">Mitchell 2010</a>, thrombosis risk stratification is likely to be required for the institution of LMWH‐based or any other type of anticoagulant‐based prophylaxis. This information is likely to be very relevant for all paediatric populations with a higher risk of thrombosis development, given that CVCs are potentially the most relevant thrombosis risk factor in place (<a href="./references#CD005982-bbs2-0072" title="O'BrienSH , CandrilliSD . In the absence of a central venous catheter, risk of venous thromboembolism is low in critically injured children, adolescents, and young adults: evidence from the National Trauma Data Bank. Pediatric Critical Care Medicine2011;12(3):251-6.">O'Brien 2011</a>). </p> <p><a href="./references#CD005982-bbs2-0031" title="VegtingIL , TabbersMM , BenningaMA , WIldeJC , SerlieMJ , TasTA , et al. Prophylactic anticoagulation decreases catheter-related thrombosis and occlusion in children with home parenteral nutrition. Journal of Parenteral and Enteral Nutrition2012;36(4):456-62. ">Vegting 2012</a> was a single centre observational study from children requiring total parenteral nutrition (TPN) administered through a CVC. In this study, patients on TPN receiving either LMWH (for example, nadroparin in a single dose of 80 IU/kg targeting an anti‐Xa between 0.1 and 0.3) or an oral vitamin K antagonist (VKA) (acenocumarol, targeting an international normalised ratio (INR) between 2.0 and 3.0) were compared to patients from the same centre in whom anticoagulation prophylaxis was not used. Of note, approximately 75% of patients included in the prophylaxis arm were previously included in the non‐prophylaxis group as the clinic's anticoagulation policy was changed. The CVC‐related outcomes of this cohort were CVC‐related thrombosis, infection and obstruction. In summary, patients receiving thromboprophylaxis (n = 18; 16 LMWH, 2 VKA) had a lower rate of thrombosis (6%) in comparison to the children not receiving prophylaxis (n = 14; 33%; P = 0.034). Moreover, per 1000 TPN days, the prophylaxis and non‐prophylaxis groups had 0.1 and 2.6 CVC occlusions (P = 0.04) and 2.1 and 4.6 infections (P = 0.06), respectively, with a three‐year infection‐free survival of 46% and 19%, respectively (P = 0.03). No bleeding occurred in either group and the study authors concluded that anticoagulation prophylaxis significantly decreased CVC‐related complications in children receiving long‐term TPN. <a href="./references#CD005982-bbs2-0009" title="DiamondCE , HennesseyC , MeldauJ , GuelcherCJ , GuerreraMF , ConklinLS , et al. Catheter-related venous thrombosis in hospitalized pediatric patients with inflammatory bowel disease: incidence, characteristics, and role of anticoagulant thromboprophylaxis with enoxaparin. Journal of Pediatrics2018;198:53-9. ">Diamond 2018</a> retrospectively compared the rate of CVC‐related thrombosis in children hospitalised for inflammatory bowel disease requiring a CVC with and without thromboprophylaxis with enoxaparin (&lt; 40 kg: 0.5 mg/kg subcutaneously every 12 h; 40 kg and above: 40 mg subcutaneously daily). CVC‐related thrombosis occurred in 0/24 (0%) of cases with LMWH, compared to 5/23 (22%) of cases where no prophylaxis was given. This study did not find differences between groups in terms of red cell transfusion requirement or haemoglobin nadir, as a proxy of bleeding complications. </p> <p>The differing conclusions between these studies (<a href="./references#CD005982-bbs2-0009" title="DiamondCE , HennesseyC , MeldauJ , GuelcherCJ , GuerreraMF , ConklinLS , et al. Catheter-related venous thrombosis in hospitalized pediatric patients with inflammatory bowel disease: incidence, characteristics, and role of anticoagulant thromboprophylaxis with enoxaparin. Journal of Pediatrics2018;198:53-9. ">Diamond 2018</a>; <a href="./references#CD005982-bbs2-0031" title="VegtingIL , TabbersMM , BenningaMA , WIldeJC , SerlieMJ , TasTA , et al. Prophylactic anticoagulation decreases catheter-related thrombosis and occlusion in children with home parenteral nutrition. Journal of Parenteral and Enteral Nutrition2012;36(4):456-62. ">Vegting 2012</a>) and this systematic review may be explained by differences in the baseline thrombosis risk of the study population and in the study methodology. More specifically, the population included in <a href="./references#CD005982-bbs2-0031" title="VegtingIL , TabbersMM , BenningaMA , WIldeJC , SerlieMJ , TasTA , et al. Prophylactic anticoagulation decreases catheter-related thrombosis and occlusion in children with home parenteral nutrition. Journal of Parenteral and Enteral Nutrition2012;36(4):456-62. ">Vegting 2012</a> was a much more homogeneous one, recognizably amongst the highest risk groups for CVC‐related thrombosis development (<a href="./references#CD005982-bbs2-0038" title="AndrewM , MarzinottoV , PencharzP , ZlotkinS , BurrowsP , IngramJ , et al. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. Journal of Pediatrics1995;126(3):358-63.">Andrew 1995</a>). In such patients, the nature of the infusate, leading to local vessel wall inflammation, in addition to protein precipitation within the catheter lumen contribute to a likely high rate of CVC‐related complications. <a href="./references#CD005982-bbs2-0009" title="DiamondCE , HennesseyC , MeldauJ , GuelcherCJ , GuerreraMF , ConklinLS , et al. Catheter-related venous thrombosis in hospitalized pediatric patients with inflammatory bowel disease: incidence, characteristics, and role of anticoagulant thromboprophylaxis with enoxaparin. Journal of Pediatrics2018;198:53-9. ">Diamond 2018</a> also included a patients at high risk of thrombosis, combining multiple risk factors such as active inflammatory bowel disease, hospitalisation and a CVC. Their studies also included older children and adolescents (median age: 14 years), who are at higher risk of thrombosis (<a href="./references#CD005982-bbs2-0037" title="AndrewM , DavidM , AdamsM , AliK , AndersonR , BarnardD , BernsteinM , BrissonL , CairneyB , DeSaiD . Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood1994;83(5):1251-7.">Andrew 1994</a>). </p> <p>Depending on the time of CVC insertion, thrombosis risk factors will have greater or lesser importance. Given the study design of <a href="./references#CD005982-bbs2-0031" title="VegtingIL , TabbersMM , BenningaMA , WIldeJC , SerlieMJ , TasTA , et al. Prophylactic anticoagulation decreases catheter-related thrombosis and occlusion in children with home parenteral nutrition. Journal of Parenteral and Enteral Nutrition2012;36(4):456-62. ">Vegting 2012</a>, the interpretation of the results is limited as 13/18 patients from the thromboprophylaxis arm had their CVC inserted and been exposed to total parenteral nutrition for a considerable time before they entered "the intervention study arm", likely leading to exposure to risk factors in an unbalanced and different manner. In <a href="./references#CD005982-bbs2-0009" title="DiamondCE , HennesseyC , MeldauJ , GuelcherCJ , GuerreraMF , ConklinLS , et al. Catheter-related venous thrombosis in hospitalized pediatric patients with inflammatory bowel disease: incidence, characteristics, and role of anticoagulant thromboprophylaxis with enoxaparin. Journal of Pediatrics2018;198:53-9. ">Diamond 2018</a>, patients received thromboprophylaxis at the primary care team's discretion, which may over‐estimate the effectiveness of LMWH, as patients with unmeasured variables that increased their thrombosis risk are more likely to be exposed to the intervention. </p> <p>In comparison, several meta‐analyses have reported a beneficial effect of LMWH to prevent venous thromboembolism in adult populations, for example in hospitalised patients (<a href="./references#CD005982-bbs2-0058" title="LederleFA , ZyllaD , MacDonaldR , WiltTJ . Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine2011;155(9):602-15.">Lederle 2011</a>), in adult patients with cancer and a CVC (<a href="./references#CD005982-bbs2-0055" title="KahaleLA , HakoumMB , TsolakianIG , AlturkiF , MatarCF , TerrenatoI , et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database of Systematic Reviews2018, Issue 6. [DOI: 10.1002/14651858.CD006650.pub5]">Kahale 2018</a>), and in adults hospitalised in medical‐surgical intensive care units (<a href="./references#CD005982-bbs2-0036" title="AlhazzaniW , LimW , JaeschkeRZ , MuradMH , CadeJ , CookDJ . Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Critical Care Medicine2013;41(9):2088-98.">Alhazzani 2013</a>). However, any benefit on mortality remains unclear. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005982-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/urn:x-wiley:14651858:media:CD005982:CD005982-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD005982-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_t/tCD005982-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#CD005982-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005982-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/urn:x-wiley:14651858:media:CD005982:CD005982-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005982-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_t/tCD005982-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#CD005982-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005982-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/urn:x-wiley:14651858:media:CD005982:CD005982-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LWMH versus control, Outcome 1: All CVC‐related thrombosis" data-id="CD005982-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_t/tCD005982-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: LWMH versus control, Outcome 1: All CVC‐related thrombosis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/references#CD005982-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005982-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/urn:x-wiley:14651858:media:CD005982:CD005982-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LWMH versus control, Outcome 2: Symptomatic CVC‐related thrombosis" data-id="CD005982-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_t/tCD005982-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: LWMH versus control, Outcome 2: Symptomatic CVC‐related thrombosis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/references#CD005982-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005982-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/urn:x-wiley:14651858:media:CD005982:CD005982-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LWMH versus control, Outcome 3: Asymptomatic CVC‐related thrombosis" data-id="CD005982-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_t/tCD005982-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: LWMH versus control, Outcome 3: Asymptomatic CVC‐related thrombosis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/references#CD005982-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005982-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/urn:x-wiley:14651858:media:CD005982:CD005982-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LWMH versus control, Outcome 4: Major bleeding" data-id="CD005982-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_t/tCD005982-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: LWMH versus control, Outcome 4: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/references#CD005982-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005982-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/urn:x-wiley:14651858:media:CD005982:CD005982-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LWMH versus control, Outcome 5: Minor bleeding" data-id="CD005982-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_t/tCD005982-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: LWMH versus control, Outcome 5: Minor bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/references#CD005982-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/media/CDSR/CD005982/image_n/nCD005982-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005982-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Does low molecular weight heparin prevent central venous catheter‐related thrombosis compared to control in children?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low molecular weight heparin (LMWH) for prevention of central venous catheter (CVC)‐related thrombosis in children</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with a CVC<br/><b>Setting:</b> paediatric tertiary care hospital<br/><b>Intervention:</b> LMWH<br/><b>Comparison:</b> control<sup>a</sup> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with LMWH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>CVC‐related thrombosis</b> </p> <p>(follow up ranged from 30 to 64 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.68<br/>(0.27 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>787<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/>(24 to 156) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic CVC‐related thrombosis</b> </p> <p>(assessed with venography;<br/>follow up ranged from 30 to 44 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/>(0.21 to 4.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>158<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/>(8 to 185) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Asymptomatic CVC‐related thrombosis</b> </p> <p>(assessed with venography;<br/>follow up ranged from 30 to 44 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.17<br/>(0.45 to 3.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>158<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000<br/>(39 to 305) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> <p>(assessed with clinical findings;<br/>follow up ranged from 30 days to 64 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.27<br/>(0.05 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>813<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(1 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor bleeding</b> </p> <p>(assessed with clinical findings;<br/>follow up ranged from 30 to 64 days) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>813<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> reported minor bleeding in 53.3% of patients in the reviparin arm and in 44.7% of patients in the low‐dose UFH arm (RR 1.20, 95% CI 0.91 to 1.58). <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> reported no minor bleeding in either arm. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality during study period</b> </p> <p>(follow up ranged from 30 to 64 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>813<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One study reported two deaths during the study period. Both were unrelated to VTE and occurred in the low‐dose UFH arm (<a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a>). One study, including paediatric patients with acute lymphoblastic leukaemia, shows similar 5‐year mortality (<a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>CVC</b> : central venous catheter; <b>LMWH</b> : low molecular weight heparin; <b>RR:</b> risk ratio; <b>UFH</b>: unfractionated heparin </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Control: In <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a> the control group received low‐dose UFH and in <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> the control group received low‐dose UFH flushes<br/><sup>b</sup> Downgraded two steps because of serious risk of bias and inconsistency. Both studies were open‐label trials with no blinding of intervention allocation. In <a href="./references#CD005982-bbs2-0001" title="GreinerJ , SchrappeM , ClaviezA , ZimmermannM , NiemeyerC , KolbR , et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica2019;104(4):756-65. ">Greiner 2018</a>, substantial deviation from the intended intervention might affect results. Both studies reported differing effects of LMWH<br/><sup>c</sup> Downgraded two steps because of serious risk of bias and imprecision. Underpowered study; <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> was closed prematurely due to slow recruitment rate<br/><sup>d</sup> Downgraded two steps because of serious risk of bias and imprecision. Underpowered study; <a href="./references#CD005982-bbs2-0002" title="MassicotteP , JulianJA , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research2003;109(2-3):101-8. ">Massicotte 2003</a> was closed prematurely due to slow recruitment rate<br/><sup>e</sup> Downgraded two steps because of serious risk of bias and imprecision (attributable to small number of events)<br/><sup>f</sup> Downgraded three steps because of serious risk of bias and imprecision (attributable to small number of events) and inconsistency (attributable to important differences in outcome definition)<br/><sup>g</sup> Downgraded two steps because of inconsistency and imprecision (attributable to small number of events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Does low molecular weight heparin prevent central venous catheter‐related thrombosis compared to control in children?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/full#CD005982-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005982-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LWMH versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All CVC‐related thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.27, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Symptomatic CVC‐related thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Asymptomatic CVC‐related thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.05, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LWMH versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005982.pub3/references#CD005982-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005982.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005982-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005982-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005982-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD005982-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD005982-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD005982-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005982-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005982\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005982\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005982\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005982\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005982\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005982.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005982.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005982.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005982.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005982.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714464820"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005982.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714464824"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005982.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6f574b1d9377',t:'MTc0MDcxNDQ2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 